Biosimilar Development News

  1. EirGenix Signed The Commercial Licensing Agreement For Its Second HER2 Biosimilar Asset EG1206A 11/12/2025

    EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosimilar, EG1206A (Pertuzumab Biosimilar to Roche Perjeta®), covering all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan. The agreement further strengthens the two companies' collaborative development of the HER2 biosimilar product.

  2. Sandoz Signs Global License Agreement To Commercialize Breast Cancer Biosimilar pertuzumab 11/12/2025

    Sandoz, the global leader in affordable medicines, today announced the signing of a global license agreement to commercialize a proposed biosimilar of oncology medicine pertuzumab.

  3. UK High Court Rules In Favor Of Alvotech Paving Way For Manufacture And Market Entry Of AVT06, Biosimilar To Eylea® (aflibercept) 11/10/2025

    Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom.

  4. Bio-Thera Solutions Expands Partnership With Dr. Reddy's Through An Exclusive Commercialization And License Agreement For BAT2306, A Proposed Biosimilar Candidate To Cosentyx (Secukinumab), In Southeast Asia 11/10/2025

    Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that it has entered into an exclusive commercialization and license agreement with Dr. Reddy’s Laboratories Ltd., for BAT2306, a proposed biosimilar candidate to Cosentyx (secukinumab).

  5. Samsung Bioepis Reaches Settlement Agreement For PYZCHIVA (ustekinumab) In Europe 11/6/2025

    Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential.

  6. Mark Cuban Cost Plus Drug Company Expands Access With Addition Of Starjemza® (ustekinumab-hmny) To Give Patients More Power Over Prescription Costs 11/6/2025

    Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) today announced the addition of Starjemza®, a new biosimilar medication, to its growing portfolio of affordable prescription drugs.

  7. Alvotech And Advanz Pharma Receive Marketing Authorisations For Gobivaz®, A Biosimilar To Simponi® (golimumab), From The MHRA 11/6/2025

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisations for all four presentations of Gobivaz®, Alvotech’s biosimilar to Simponi® (golimumab).

  8. Hikma Pharmaceuticals Announces The Launch Of STARJEMZA (Ustekinumab-Hmny) Injection, A Biosimilar Referencing STELARA (Ustekinumab) Injection 11/6/2025

    Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced the launch of STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing STELARA (ustekinumab) Injection.

  9. In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650M Plus Royalties 11/4/2025

    Evotec SE, a life science company that is pioneering the future of drug discovery and development, today announced the successful signing of the sale of the Just - Evotec Biologics Toulouse site to Sandoz AG, a global leader in generic and biosimilar medicines.

  10. Sandoz Boosts In-House Biosimilars Capabilities By Signing Agreement To Acquire Just-Evotec Biologics EU SAS In Toulouse 11/4/2025

    Sandoz, the global leader in affordable medicines, today announced a strategic agreement with Evotec SE to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS) which includes the Toulouse manufacturing site.